Please enable JavaScript.
Coggle requires JavaScript to display documents.
InnoVate AMR (Not considered (Do not consider antibiotic resistance, Do…
InnoVate AMR
Not considered
-
Do not consider swine, poultry or aquaculture (fish or shellfish)
-
-
-
-
-
Are to develop alternatives solutions to antibiotics not relevant to low and middle income countries
-
Are designed for fundamental research, corresponding to TRL 1 and 2 (See Annex 2)
-
Essential
Develop innovative veterinary solutions, focusing on product development, to reduce the therapeutic (prevention and control) and non-therapeutic (growth promotion) use of antibiotics, while still protecting animal health and welfare.
Strong involvement of researchers, manufacturers and other organizations, as well as early involvement of regulatory authorities, in developing countries is critical when working towards accelerating the registration of veterinary products.
Gender equity: Proposals need to demonstrate how the project will involve women from all participating organisations comprising the research team and throughout the research process.
Commercialisation and Adoption Plan of the innovation should also demonstrate how women will be involved; including a strategy that explains how gender implication will be considered."
Environment: Proposals need to demonstrate that they have considered the potential environmental impacts of their activities, detailing potential benefits and describing how any potential harmful effects will be mitigated.
Understand and address the local contexts and realities which drive antibiotic-usage patterns on farms in developing countries, to ensure relevant innovations that are appropriate for the ultimate uptake and use by farmers, veterinarians and paraveterinarians in developing countries.
These solutions must target the prevention and control of infectious diseases of importance in low and middle income countries and the reduction of the use of antibiotics as growth promoters.
-
Funding Bodies
IDRC
-
Generate local solutions, bringing choice and change to those who need it most in the developing world
DHSC
Helping people to live more independent, healthier lives for longer
GAMRIF was established to support early-stage, innovative research and development, specifically targeting neglected and underinvested areas in the field of antimicrobial resistance (AMR).
Ultimate Outcome
Reduce the threat of antibiotic resistance to human health by minimising the misuse of antibiotics and the development and spread of antibiotics resistance in developing countries, through the development and uptake of innovative veterinary products.
-
Highest Priority
Present a compelling justification for the proposed innovative veterinary solution, are scientifically sound and clearly describe how this approach will curb antibiotic use and the development of antibiotic resistance in the livestock and aquaculture sectors in low and middle income countries
-
Support innovations at the technology readiness level (TRL) 3 to 6 (see Annex 2 for further information), that is early-stage product development, excluding fundamental research
Demonstrate strong capacity to generate timely results based on specific milestones and within the allocated budget
Include and describe a future ‘Commercialization and Adoption plan’ for the veterinary solutions to be developed and ready for use in developing countries
Include and describe effective partnerships with organizations in low and middle income countries (refer to Frequently Asked Questions)
Show an awareness of medicines regulation and/or the intent to engage with a Government Regulatory Body for veterinary medicines in low and middle income countries.